Criteria for retrospective assessment of the actual clinical behavior of at any stage of the disease in patients with FL
Indolent clinical behavior . | Aggressive clinical behavior . |
|---|---|
| Slowly progressive or waxing and waning disease during watchful waiting over at least 3 mo | Rapid progression/enlargement of a tumor mass at one or more localizations within 3 mo |
| OR | AND/OR |
| On treatment: good tumor response (CR/PR)36 after treatment with CVP or chlorambucil or chlorambucil/prednisone or fludarabine in first or second line | Development of B symptoms and elevation of LDH level after previously normal levels in the preceding 3 mo |
| AND | AND/OR |
| Normal levels of LDH and no B symptoms* | Progressive disease during successive treatment with 2 or more of the following treatment protocols: CVP, chlorambucil, chlorambucil/prednisone, and fludarabine. |
Indolent clinical behavior . | Aggressive clinical behavior . |
|---|---|
| Slowly progressive or waxing and waning disease during watchful waiting over at least 3 mo | Rapid progression/enlargement of a tumor mass at one or more localizations within 3 mo |
| OR | AND/OR |
| On treatment: good tumor response (CR/PR)36 after treatment with CVP or chlorambucil or chlorambucil/prednisone or fludarabine in first or second line | Development of B symptoms and elevation of LDH level after previously normal levels in the preceding 3 mo |
| AND | AND/OR |
| Normal levels of LDH and no B symptoms* | Progressive disease during successive treatment with 2 or more of the following treatment protocols: CVP, chlorambucil, chlorambucil/prednisone, and fludarabine. |
CR indicates complete remission; PR, partial remission.
B symptoms included more than 10% weight loss within 6 months, night sweats, and fever more than 38†C.